Evidence map›Paper›PMID 41210957›Full record

ArticleiScience2025

Flavivirus-based bivalent nanoparticle vaccines induce neutralizing antibodies and Th1 responses against flavivirus and coupling antigens.

Koga Ii, Fumitaka Sato, Yu Hatakeyama, Hidehiko Suzuki, Takafumi Noguchi, Kotaro Ishida, Masashi Arakawa, Kazumasa Nakamura, Ryuta Iwatsuki, Cong Thanh Nguyen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. RNase L Regulates Antiviral Responsiveness through Cleavage of XBP1 mRNA.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Koga IiDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Fumitaka SatoDepartment of Microbiology, Kindai University Faculty of Medicine, 377-2 Ōnohigashi, Ōsakasayama, Osaka 589-0014, Japan.
Yu HatakeyamaDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Hidehiko SuzukiThe Research Foundation for Microbial Diseases of Osaka University, 3-1 Yamadaoka, Suita Osaka 565-0871, Japan.
Takafumi NoguchiThe Research Foundation for Microbial Diseases of Osaka University, 3-1 Yamadaoka, Suita Osaka 565-0871, Japan.
Kotaro IshidaDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Masashi ArakawaDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Kazumasa NakamuraDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Ryuta IwatsukiDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.
Cong Thanh NguyenDepartment of Microbiology, Kindai University Faculty of Medicine, 377-2 Ōnohigashi, Ōsakasayama, Osaka 589-0014, Japan.
Akiho YoshidaThe Research Foundation for Microbial Diseases of Osaka University, 3-1 Yamadaoka, Suita Osaka 565-0871, Japan.
Nobuyuki TanakaDivision of Tumor Immunobiology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshimashiode, Natori 981-1293, Miyagi, Japan.
Ikuo TsunodaDepartment of Microbiology, Kindai University Faculty of Medicine, 377-2 Ōnohigashi, Ōsakasayama, Osaka 589-0014, Japan.
Hirotaka EbinaThe Research Foundation for Microbial Diseases of Osaka University, 3-1 Yamadaoka, Suita Osaka 565-0871, Japan.
Eiji MoritaDepartment of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, 3 Bunkyo-cho, Hirosaki 036-8561, Aomori, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective vaccines against flaviviruses, including Japanese encephalitis virus (JEV), are widely used. We developed antigen-loaded nanoparticle vaccines, using JEV virus-like particles (JEV-VLPs) as carriers. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (S-RBD) was covalently coupled to specific peptide insertion sites on the JEV envelope protein. Mice immunized with these coupled particles (JEprME-S-RBD) produced high levels of neutralizing antibodies against both JEV and SARS-CoV-2, with broad activity against multiple SARS-CoV-2 variants. These mice also had a larger number of interferon (IFN)-γ-producing cells with higher levels of anti-S-RBD IgG2a production than mice receiving the JEV-VLP and S-RBD without coupling. These results suggested the induction of T helper (Th) 1 immune responses. We also constructed JEV nanoparticles coupled with human parvovirus B19 RBD, which efficiently induced neutralizing antibodies against both JEV and parvovirus. Therefore, flaviviral nanoparticles can serve as versatile multivalent vaccine platforms by incorporating neutralizing epitopes from different pathogens.

Indexed as

Biological sciencesImmunologynatural sciences

Identifiers

PMID41210957
PMCPMC12589883

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.